Cargando…
Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry
BACKGROUND AND OBJECTIVES: It is unclear whether more potent P2Y12 inhibitors are of benefit to older patients who are at high risk for both ischemia and bleeding. We conducted an observational study to compare the clinical outcomes of clopidogrel and ticagrelor uses in older patients with an acute...
Autores principales: | Zhang, Yunnan, Peng, Wenxing, Shi, Xiujin, Han, Jialun, Wang, Yifan, Fang, Zhenwei, Lin, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964993/ https://www.ncbi.nlm.nih.gov/pubmed/35369358 http://dx.doi.org/10.3389/fcvm.2022.859962 |
Ejemplares similares
-
Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: A cohort study from china
por: Peng, Wenxing, et al.
Publicado: (2022) -
Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Xi, Ziwei, et al.
Publicado: (2021) -
Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019) -
Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019) -
Impact of Ticagrelor vs. Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention After Risk Stratification With the CHA(2)DS(2)-VASc Score
por: Na, Kun, et al.
Publicado: (2022)